Calcitriol: Effects of a Calcitriol

Welcome To Plenus Pharmaceuticals (P) Ltd

Plenus Pharmaceuticals is built on its meaning of completeness in pharmaceutical field through our quality healthcare service that leads to healthy life everywhere. It is complete healthcare in every aspect where there is no compromise with quality of products, ensuring full satisfaction to concerned entities.

A calcitriol administration protocol was used with patients beginning on June 1, 2001. Mean serum intact parathyroid hormone , calcium, and phosphorous levels from the three months preceding and three months following initiation of dialysis were measured. A significant difference in iPTH levels between patients treated under the calcitriol protocol and patients in the control group was observed. Patients with end-stage renal disease frequently develop secondary hyperparathyroidism because of decreased production of 1,25(OH)2-vitamin D (calcitriol) in the kidneys. The onset of secondary hyperparathyroidism occurs early in chronic renal failure. Patients with glomerular filtration rates (GFRs) as high as 60 mL/min/1.73 m2 may begin to produce decreased levels of calcitriol, resulting in increased intact parathyroid hormone and increased serum phosphorous levels.